Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 May 17

PMID 28509852

Citations 35

Authors

Diego J Maselli

Holly Keyt

Marcos I Restrepo

Affiliations

Soon will be listed here.

Abstract

The management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include , Methicillin-resistant , species and non-tuberculous (NTM). These challenges prompted scientists to deliver antimicrobial agents through the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Subsequent research advances focused on the development of antibiotic agents able to achieve high tissue concentrations capable of reducing the bacterial load of difficult-to-treat organisms in hosts with chronic respiratory conditions. In this review, we focus on the evidence regarding the use of antibiotic therapies administered through the respiratory system via inhalation, nebulization or aerosolization, specifically in patients with chronic respiratory diseases that include CF, non-CF bronchiectasis and NTM. However, further research is required to address the potential benefits, mechanisms of action and applications of inhaled antibiotics for the management of difficult-to-treat infections in patients with chronic respiratory diseases.

Citing Articles

Impact of Hydrophobic, Hydrophilic, and Mucus-Binding Motifs on the Therapeutic Potential of Ceftazidime Analogs for Pulmonary Administration.

Apley K, Johnson S, Qian J, Munasinghe I, Klaus J, Patel S Antibiotics (Basel). 2025; 14(2).

PMID: 40001420 PMC: 11852049. DOI: 10.3390/antibiotics14020177.

Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.

Dallal Bashi Y, Mairs R, Murtadha R, Kett V Pharmaceutics. 2025; 17(1).

PMID: 39861758 PMC: 11768398. DOI: 10.3390/pharmaceutics17010111.

Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.

Maloney Norcross S, Levin L, Hickey A, Hill D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770469 PMC: 11728674. DOI: 10.3390/ph17121628.

Therapeutic Interventions for Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.

Alqasmi M J Clin Med. 2024; 13(21).

PMID: 39518670 PMC: 11547045. DOI: 10.3390/jcm13216530.

Anti-Persisters Activity of Culture Filtrates against in Artificial Sputum Medium.

Bianchi M, Esin S, Kaya E, Batoni G, Maisetta G Int J Mol Sci. 2024; 25(13).

PMID: 39000222 PMC: 11241021. DOI: 10.3390/ijms25137113.

References

Flume P, Clancy J, Retsch-Bogart G, Tullis D, Bresnik M, Derchak P . Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016; 15(6):809-815. DOI: 10.1016/j.jcf.2016.05.001. View

Murphy T, Anbar R, Lester L, Nasr S, Nickerson B, VanDevanter D . Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004; 38(4):314-20. DOI: 10.1002/ppul.20097. View

Flume P, VanDevanter D, Morgan E, Dudley M, Loutit J, Bell S . A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016; 15(4):495-502. DOI: 10.1016/j.jcf.2015.12.004. View

Nixon G, Armstrong D, Carzino R, Carlin J, Olinsky A, Robertson C . Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001; 138(5):699-704. DOI: 10.1067/mpd.2001.112897. View

Cunningham S, Prasad A, Collyer L, Carr S, Lynn I, Wallis C . Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child. 2001; 84(5):432-3. PMC: 1718770. DOI: 10.1136/adc.84.5.432. View

Gellatly S, Hancock R . Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013; 67(3):159-73. DOI: 10.1111/2049-632X.12033. View

Chono S, Tanino T, Seki T, Morimoto K . Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm. 2008; 34(10):1090-6. DOI: 10.1080/03639040801958421. View

Olivier K, Griffith D, Eagle G, McGinnis 2nd J, Micioni L, Liu K . Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2016; 195(6):814-823. PMC: 5363966. DOI: 10.1164/rccm.201604-0700OC. View

Burke D, Harrison M, Fleming C, McCarthy M, Shortt C, Sulaiman I . Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J Cyst Fibros. 2016; 16(2):291-298. DOI: 10.1016/j.jcf.2016.09.008. View

10.

Saiman L, Siegel J, LiPuma J, Brown R, Bryson E, Chambers M . Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014; 35 Suppl 1:S1-S67. DOI: 10.1086/676882. View

11.

Tullis D, Burns J, Retsch-Bogart G, Bresnik M, Henig N, Lewis S . Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros. 2013; 13(3):296-305. DOI: 10.1016/j.jcf.2013.08.011. View

12.

Rose S, Neville M, Gupta R, Bermudez L . Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One. 2014; 9(9):e108703. PMC: 4180930. DOI: 10.1371/journal.pone.0108703. View

13.

Olivier K, Shaw P, Glaser T, Bhattacharyya D, Fleshner M, Brewer C . Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014; 11(1):30-5. PMC: 3972984. DOI: 10.1513/AnnalsATS.201307-231OC. View

14.

Chen H, Woods A, Forbes B, Jones S . Controlled drug release from lung-targeted nanocarriers via chemically mediated shell permeabilisation. Int J Pharm. 2016; 511(2):1033-41. DOI: 10.1016/j.ijpharm.2016.08.012. View

15.

Dasenbrook E, Konstan M, VanDevanter D . Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros. 2014; 14(3):370-5. PMC: 4417393. DOI: 10.1016/j.jcf.2014.11.005. View

16.

Serisier D, Bilton D, Soyza A, Thompson P, Kolbe J, Greville H . Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013; 68(9):812-7. PMC: 4770250. DOI: 10.1136/thoraxjnl-2013-203207. View

17.

Stass H, Delesen H, Nagelschmitz J, Staab D . Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J Aerosol Med Pulm Drug Deliv. 2014; 28(2):106-15. DOI: 10.1089/jamp.2013.1056. View

18.

Breidenstein E, de la Fuente-Nunez C, Hancock R . Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011; 19(8):419-26. DOI: 10.1016/j.tim.2011.04.005. View

19.

Konstan M, Flume P, Galeva I, Wan R, Debonnett L, Maykut R . One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2015; 51(4):372-8. DOI: 10.1002/ppul.23358. View

20.

Seitz A, Olivier K, Adjemian J, Holland S, Prevots D . Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012; 142(2):432-439. PMC: 3425339. DOI: 10.1378/chest.11-2209. View